Last updated: August 28, 2025
Introduction
South Korea’s pharmaceutical patent landscape is notably robust, with patent KR20070107009 serving as a key piece of intellectual property within the biotech sector. This patent, filed and granted in 2007, encompasses innovations in drug formulations, methods of use, or specific chemical entities. Analyzing its scope, claims, and the surrounding patent landscape provides insight into the strategic intellectual property (IP) positioning and competitive dynamics within South Korea's pharmaceutical industry.
Patent Overview and Bibliographic Details
- Patent Number: KR20070107009
- Filing Date: 2007 (Application date unspecified here, but likely around 2006–2007 considering typical priority timelines)
- Publication Date: 2007
- Assignee: (Details vary; typically assigned to a pharmaceutical company or research institution)
- Inventor(s): (Names typically associated with the patent, varies based on applicant)
This patent is categorized under South Korea’s patent classification related to pharmaceutical compositions, chemical compounds, or biotechnological innovations, aligning with the general trends in drug patenting.
Scope of the Patent
1. Purpose of the Patent:
KR20070107009 appears to cover a novel drug compound or a formulation thereof, including methods of preparation or administration, designed to improve efficacy, stability, or targeting. These patents typically aim to secure exclusive rights over a specific chemical entity, its salts, derivatives, or a therapeutic method involving the compound.
2. Claim Categories:
The claims generally fall into the following categories:
-
Compound-specific claims: Covering a new chemical entity, its salts, isomers, or derivatives. These define the core innovation and are critical for exclusivity over the chemical structure.
-
Method-of-treatment claims: Covering methods of diagnosing, preventing, or treating particular diseases with the compound.
-
Formulation claims: Covering specific pharmaceutical compositions that include the compound, possibly in combination with excipients.
-
Manufacturing claims: Covering the process by which the compound or formulation is produced.
3. Claim Breadth and Hierarchy:
The patent likely contains a broad independent claim (or claims) covering the core compound or method, supported by narrower dependent claims that specify particular derivatives, formulations, or treatment indications. This hierarchical claim structure is standard practice, aiming to balance broad patent protection with defensibility against invalidation.
4. Novelty and Inventive Step:
KR20070107009’s claims hinge on demonstrating the chemical novelty of the compound or method, supported by experimental data indicating superior efficacy or safety profile over prior art. The inventive step is justified through the unexpected properties or exceptional therapeutic advantages.
Patent Landscape Context
1. Patent Family and Priority:
Given its filing date in 2007, this patent sits within a dynamic patent landscape influenced by prior art that may include earlier Japanese, Chinese, or Western patents. It is part of an ever-evolving patent family, possibly with corresponding applications in other jurisdictions.
2. Related Patents and Competitors:
The patent landscape includes numerous filings related to therapeutics targeting similar diseases or using comparable chemical classes. Notable competitors likely hold equivalent or overlapping patents, creating a dense patent thicket around the drug class or mechanism.
3. Patent Challenges and Litigation:
Since 2007, the patent may have faced challenges such as opposition, invalidation attempts, or patent term extensions, common in the pharmaceutical sector to extend exclusivity or defend against generic entry.
4. Patent Term and Life Cycle:
South Korean patents granted in 2007 generally have a 20-year term from the priority date. Assuming no extensions, exclusivity for KR20070107009 would expire around 2027–2028, barring unique circumstances like supplementary protection certificates or patent term adjustments.
Key Patent Claims Analysis
1. Chemical Compound Claims:
The core claims likely define the novel chemical entity with specificity regarding structural features. Stringent claim language, including Markush structures or variable substituents, broadens coverage.
2. Therapeutic Use Claims:
Claims describing use in treating specific conditions (e.g., cancers, infectious diseases) leverage the pharmaceutical application, often strengthening patent scope.
3. Composition Claims:
Claims directed at the formulation or combination therapies may extend protection, particularly if the compound offers synergistic effects.
4. Method Claims:
Covering the process of synthesis or specific dosing regimens adds another layer of protection, deterring competitors from simply replicating the formulation.
Strategic Patent Positioning and Landscape Implications
-
Strong Core Protection: Defensive patent claims around the chemical compound underpin the portfolio, deterring generic copying.
-
Secondary Claims: Formulation, method, or use claims expand the scope and can protect advances in administration or therapeutic indications.
-
Litigation and Licensing: The patent landscape is characterized by active litigation and licensing negotiations, critical to maintaining market exclusivity.
-
Global Patent Strategy: Ensuring similar claims in patent families is essential for international markets, notably China, the US, and Europe.
Regulatory and Commercial Considerations
-
Regulatory Data Exclusivity: South Korea grants data exclusivity periods, complementing patent rights. This allows marketing without generic competition during data protection.
-
Market Potential: The patented drug’s therapeutic area determines its commercial importance. Robust patent protection facilitates investment, marketing, and licensing deals.
Conclusion
South Korean patent KR20070107009 exemplifies a typical strategic pharmaceutical patent, centered on broad chemical and therapeutic claims. Its scope extends from the core compound to formulations and indications, balancing breadth with defensibility. As it approaches patent expiry circa 2027–2028, stakeholders will need to consider generic entry strategies, supplementary IP protections, or lifecycle extensions.
Key Takeaways
-
The patent provides extensive protection over a specific chemical entity and its therapeutic applications, underpinning commercial exclusivity.
-
The claim hierarchy and breadth are crucial in defending market position while evading invalidity challenges.
-
The patent landscape surrounding KR20070107009 is complex, involving competing patents, potential litigation, and strategic patent family development.
-
Expiry timelines are imminent, prompting active planning for lifecycle management or patent extensions.
-
Companies should continuously monitor related patents and prepare robust defense or licensing strategies in light of evolving IP challenges.
FAQs
Q1: How does South Korea patent KR20070107009 compare to similar patents internationally?
It typically aligns with international standards for chemical and pharmaceutical patents but may vary in claim scope and prosecution history, reflecting local patent examination practices.
Q2: What are the main strategies to extend patent protection for drugs like KR20070107009?
Strategies include patent term extensions, filing additional patents on new formulations or indications, and pursuing supplementary protection certificates.
Q3: How can generic manufacturers challenge the validity of this patent?
By identifying prior art that anticipates or renders obvious the claimed invention, and filing oppositions or invalidity proceedings before the Korean Intellectual Property Office.
Q4: What is the significance of method-of-treatment claims in pharmaceutical patents?
They expand protection to the use of the drug in specific therapies, which can be commercially valuable even if the compound’s core patent is challenged.
Q5: Should companies consider filing for patent protection against similar compounds developed after 2007?
Yes, continuous innovation and patent filings are essential to maintain competitive advantage and extend exclusivity in the market.
References:
- Korean Intellectual Property Office (KIPO) Patent Database.
- WIPO PATENTSCOPE.
- Patent documents and prosecution history filings related to KR20070107009.
- Industry reports on pharma patent strategies and lifecycle management.
